Connect with us
  • Elysium

Premium content

Clinical trial planned for new cognitive impairment drug



Clinical stage pharma company PharmaKure is set to embark on a clinical trial of a combined drug for patients with mild cognitive impairment. 

PharmaKure has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare Regulatory Agency (MHRA) in the United Kingdom to evaluate PK051.

Unlock this article and more exclusive content every day as an NR Times subscriber. Just £24.99 / $30 / €28 per year.

Login Join Now